| 📌 The essentials On April 22, 2026, the FDA approved Lynavoy (linerixibat, GSK), an oral ileal bile acid transporter (IBAT) inhibitor, for cholestatic pruritus in adults with primary biliary cholangitis (PBC). This is the first FDA-approved therapy specifically indicated for cholestatic pruritus in PBC. It is a full approval, not accelerated, meaning the FDA reviewed actual clinical benefit data. The clinical basis: the Phase 3 GLISTEN trial (NCT03706547) enrolling 238 patients with moderate to severe cholestatic pruritus, showing statistically significant reduction in worst itch NRS score versus placebo (p less than 0.001), with rapid onset by week 2 and benefit sustained through 24 weeks. Sleep quality also improved significantly (p=0.024). Key safety consideration: diarrhea occurred in 61% of patients in GLISTEN, the majority mild to moderate. Discontinuation rate due to diarrhea was approximately 4%. What it does not do: Lynavoy is not a disease-modifying therapy for PBC. It does not slow liver disease progression or replace existing PBC treatments including UDCA or obeticholic acid. It treats the itch. |
|---|
There is a particular kind of suffering that does not show up well on a lab report. Cholestatic pruritus, the relentless, internal itch caused by bile acid accumulation in primary biliary cholangitis, is one of them. It does not scratch away. It does not respond to antihistamines. It keeps patients awake at 3 a.m., disrupts concentration, and compounds the psychological weight of already managing a progressive autoimmune liver disease.
On April 22, 2026, the FDA approved Lynavoy (linerixibat), GSK’s oral IBAT inhibitor, specifically for cholestatic pruritus in adults with PBC. It is the first medicine approved in the United States for this indication. As approvals go, this is one where the clinical evidence and the patient need are unusually well-aligned.
What Is Primary Biliary Cholangitis?
PBC is a rare, chronic autoimmune liver disease in which the immune system mistakenly attacks the small bile ducts inside the liver. As those ducts are damaged and scarred over time, bile cannot drain properly; it backs up into the liver and eventually into the bloodstream.
The disease affects roughly 1 in 1,000 women over 40, though it is underdiagnosed and can affect men as well. Without effective management, PBC can progress to cirrhosis, liver failure, and the need for transplantation.
Cholestatic pruritus affects up to 89% of people with PBC at some point during the disease. It is caused by the accumulation of bile acids in the skin and blood, and it is notoriously difficult to treat. Before Lynavoy, available options were largely off-label, inconsistently effective, and sometimes poorly tolerated. For many patients, managing the itch meant cycling through treatments that did not really work.
How Linerixibat Works
Linerixibat is an ileal bile acid transporter (IBAT) inhibitor. Under normal circumstances, the IBAT protein in the small intestine reabsorbs bile acids from the gut back into circulation, a recycling loop that keeps the body’s bile acid pool stocked. In PBC, where the liver is already struggling to process that pool, this recycling makes the problem worse.
Linerixibat blocks the IBAT pump in the gut, preventing that reabsorption. Fewer bile acids recirculate. Levels in the blood and skin drop. And for many patients, so does the itch.
It is a targeted, mechanistically rational approach. Because it acts locally in the gut rather than systemically, it avoids some of the side effects associated with older therapies like cholestyramine.
| Why does blocking gut bile acid recycling help with itch in the skin? Bile acids that recirculate from the gut end up in systemic blood, and from there accumulate in peripheral tissues including the skin. The exact mechanism by which bile acids trigger itch is not fully established; it likely involves bile acid receptors on sensory nerve fibers, specifically the TGR5 receptor and the bile acid-sensitive ion channel TRPA1. The clinical correlation between bile acid levels and itch severity is well-documented. Reducing the circulating load through IBAT inhibition targets the source of the symptom rather than suppressing the itch signal downstream. |
|---|
The GLISTEN Trial: What the Data Shows
The pivotal GLISTEN Phase 3 trial (NCT03706547) enrolled 238 patients with PBC and moderate to severe cholestatic pruritus. Participants were randomized to linerixibat or placebo for 24 weeks. The primary endpoint was itch intensity, measured using the Numerical Rating Scale (NRS) for worst itch, a validated patient-reported outcome that captures what patients actually experience rather than a laboratory surrogate.
| Endpoint | Result | Statistical significance |
|---|---|---|
| Worst itch NRS reduction vs. placebo | Statistically significant mean difference | p less than 0.001 |
| Sleep quality improvement (NRS) | Significant improvement vs. placebo | p=0.024 |
| Onset of itch benefit | Detectable by week 2 | — |
| Duration of benefit | Sustained through 24 weeks | — |
| Diarrhea (all grade) | 61% in linerixibat arm | Discontinuation rate ~4% |
| Abdominal pain | 18% in linerixibat arm | Discontinuation rate less than 1% |
Source: GLISTEN Phase 3 trial, NCT03706547. GSK press release, April 22, 2026.
The sleep quality finding deserves equal weight as the itch reduction data. In qualitative research and patient surveys, pruritus-related sleep disruption consistently ranks as one of the most burdensome aspects of PBC, sometimes more so than concerns about disease progression. A therapy that demonstrably improves both itch intensity and sleep quality is addressing the full clinical picture of what patients report as most disruptive to their daily lives.
The diarrhea rate of 61% is notable and warrants clear communication with patients before initiating therapy. Most cases were mild to moderate, and the discontinuation rate of approximately 4% was low, but this is a side effect that will affect real-world tolerability, particularly for patients who are already managing fatigue and GI sensitivity as part of their PBC picture. Clinicians prescribing Lynavoy will need to set expectations carefully and discuss management strategies, including dose timing, dietary considerations, and when dose adjustment is appropriate.
The full approval status matters here. This is not accelerated approval based on a surrogate biomarker. The FDA reviewed patient-reported outcome data on actual symptom reduction and determined it met the standard for substantial evidence of clinical benefit. That is a meaningful regulatory bar, and the GLISTEN data cleared it.
Dr. Christopher Bowlus, Chief of Gastroenterology and Hepatology at UC Davis Health and a principal investigator in the linerixibat program, characterized the approval as representing an important opportunity to improve the lives of people with PBC who struggle with uncontrolled and often debilitating pruritus. That framing reflects the clinical reality: “uncontrolled and often debilitating” is not hyperbole in this patient population.
What This Approval Does Not Answer
Does treating the itch affect disease progression?
Lynavoy is approved specifically for symptom management, not as a disease-modifying therapy for PBC itself. Patients with PBC who need a medication to slow liver disease progression are managed with ursodeoxycholic acid (UDCA) or obeticholic acid. Linerixibat does not replace those. Whether there is any long-term hepatoprotective effect from reducing bile acid recirculation has not been established and should not be assumed from the GLISTEN data, which was not designed or powered to assess disease progression.
Real-world tolerability
Trial populations tend to be healthier and more closely monitored than the broader patient population. The 61% diarrhea rate in GLISTEN will bear watching in post-market use, particularly in older patients or those with baseline GI sensitivity who were not well represented in the trial. Patient registries and observational data over the next one to two years will be more informative here than the trial data alone.
Cost and access
Lynavoy carries Orphan Drug Designation, which typically supports premium pricing and seven years of market exclusivity. GSK has not yet announced U.S. list pricing. For a symptom-focused therapy in a rare disease, the cost-benefit calculus for payers is different than for a life-prolonging treatment, which could create coverage access hurdles worth monitoring. GSK’s patient support program details will matter significantly for patients navigating these conversations.
The Broader Context: IBAT Inhibitors and Cholestatic Liver Disease
Linerixibat’s approval in adult PBC is part of a broader story in hepatology. The IBAT inhibitor mechanism has already demonstrated clinical utility in pediatric cholestatic conditions. Maralixibat (Livmarli) is approved for cholestatic pruritus in Alagille syndrome, and odevixibat (Bylvay) is approved for cholestatic pruritus in progressive familial intrahepatic cholestasis (PFIC). The validation of this mechanism in adult PBC extends the evidence base for IBAT inhibition across cholestatic conditions and may support future investigation in other forms of cholestatic liver disease where pruritus remains inadequately managed.
Lynavoy is also GSK’s first FDA-approved liver medicine from its hepatology pipeline, reflecting a deliberate strategic move for a company historically stronger in respiratory and immunology. A partnership with Alfasigma S.p.A. covers global commercialization, with regulatory submissions underway in the EU, UK, Canada, and China. Whether this represents a durable GSK hepatology platform or a single-indication program will become clearer as the pipeline matures.
For context on how the FDA approaches safety monitoring for rare disease liver conditions, see our coverage of the Tavneos (avacopan) serious liver injury warning and the ongoing regulatory dispute between the FDA and Amgen over voluntary withdrawal.
For Patients and Caregivers
For adults living with PBC and cholestatic pruritus who have not achieved adequate itch relief with currently available treatments, Lynavoy adds the first indication-specific approved option in the United States. The conversation about whether it is appropriate for an individual patient belongs with a gastroenterologist or hepatologist who is familiar with the full picture of disease activity, current medications, and GI tolerance.
The PBCers Organization is the primary U.S. patient advocacy group for primary biliary cholangitis and has responded to the Lynavoy approval as a significant step forward for those dealing with chronic, uncontrolled itch. Their resources, community forums, and physician directory are the best starting point for patients navigating this diagnosis. The American Liver Foundation and the National Institute of Diabetes and Digestive and Kidney Diseases also maintain current clinical information on PBC management.
The GLISTEN trial is complete. Ongoing clinical trials for PBC and cholestatic liver disease can be searched at ClinicalTrials.gov for patients interested in research participation.
Sources
GSK FDA approval press release: GSK Announces U.S. FDA Approval of Lynavoy (linerixibat), the First and Only Medicine Approved in the US Specifically for Cholestatic Pruritus in Adults with Primary Biliary Cholangitis (PBC). April 22, 2026. gsk.com.
GLISTEN trial registration: NCT03706547. A Phase III Study to Evaluate the Efficacy and Safety of Linerixibat in Participants with Primary Biliary Cholangitis with Cholestatic Pruritus. ClinicalTrials.gov.
PBC epidemiology and pruritus burden: Primary Biliary Cholangitis: Epidemiology and Quality of Life. PMC7510845.
Cholestatic pruritus overview: Cholestatic Pruritus. StatPearls. NCBI.
IBAT inhibitor mechanism: Ileal Bile Acid Transporter Inhibitors as a Novel Therapeutic Approach. PMC7387516.
UDCA in PBC: Ursodeoxycholic Acid. StatPearls. NCBI.
Obeticholic acid FDA approval: FDA approves obeticholic acid for primary biliary cholangitis. FDA.gov.
Maralixibat FDA approval: FDA approves maralixibat chloride for Alagille syndrome. FDA.gov.
Odevixibat FDA approval: FDA approves odevixibat for pruritus in cholestatic liver disease. FDA.gov.
PBC NIDDK overview: Primary Biliary Cholangitis. NIDDK.
Orphan Drug Designation: Designating an Orphan Product. FDA.gov.
Patient resources: PBCers Organization | American Liver Foundation: PBC | NIDDK PBC | ClinicalTrials.gov: PBC pruritus
| Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about PBC treatment, including whether linerixibat is appropriate for your situation, should be made in consultation with a qualified gastroenterologist or hepatologist familiar with your individual disease status, treatment history, and current medications. |
|---|